The current role of Tofacitinib in acute severe ulcerative colitis in adult patients: A systematic review

被引：12

作者：

Mpakogiannis, Konstantinos ^{[1
]}

Fousekis, Fotios S. ^{[1
]}

Christodoulou, Dimitrios K. ^{[1
]}

Katsanos, Konstantinos H. ^{[1
,4
]}

Narula, Neeraj ^{[2
,3
]}

机构：

[1] Univ Ioannina, Fac Med, Sch Hlth Sci, Div Gastroenterol,Dept Internal Med, Ioannina, Greece

[2] McMaster Univ, Dept Med, Div Gastroenterol, Hamilton, ON, Canada

[3] McMaster Univ, Farncombe Family Digest Hlth Res Inst, Hamilton, ON, Canada

[4] Univ Ioannina, Fac Med, Dept Gastroenterol, Ioannina 45110, Greece

来源：

DIGESTIVE AND LIVER DISEASE | 2023年 / 55卷 / 10期

关键词：

Tofacitinib; Ulcerative colitis; Acute severe ulcerative colitis; Hospitalized ulcerative colitis; RESCUE THERAPY; RHEUMATOID-ARTHRITIS; SALVAGE THERAPY; MANAGEMENT; ASUC;

D O I：

10.1016/j.dld.2023.05.021

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Background: Despite rescue therapy, acute severe ulcerative colitis (ASUC) is associated with a high risk of colectomy, while treatment options remain limited. Tofacitinib, a rapidly acting Janus Kinase (JAK) inhibitor, is gaining ground as an effective alternative treatment option for the management of acute severe ulcerative colitis, which may prevent emergency colectomy.Methods: A systematic literature search of PubMed and Embase was undertaken for studies of adult patients with ASUC treated with tofacitinib.Results: In total, two observational studies, seven case series and five case reports incorporating 134 patients who received tofacitinib in ASUC were identified with a follow-up period ranging from 30 days to 14 months. Overall, the pooled colectomy rate was 23.9% (95% CI 16.6-31.2). The pooled 90-day and 6-month colectomy free rate were 79.9% (95% CI 73.1-86.7) and 71.6% (95% CI 64-79.2) respectively. The most frequent adverse event was C. Difficile infection.Conclusions: Tofacitinib appears to be a promising option for the treatment of ASUC. Randomized clinical trials are required to further access the efficacy, safety and optimal dose of tofacitinib in cases of ASUC.(c) 2023 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

引用

页码：1311 / 1317

页数：7

共 39 条

[1]

Battat Robert, 2021, Clin Gastroenterol Hepatol, V19, P511, DOI 10.1016/j.cgh.2020.03.072

[2]

Bercier B, 2020, AM J GASTROENTEROL, V115, pS1207

[3] Tofacitinib for Biologic-Experienced Hospitalized Patients With Acute Severe Ulcerative Colitis: A Retrospective Case-Control Study [J].

Berinstein, Jeffrey A. ;

Sheehan, Jessica L. ;

Dias, Michael ;

Berinstein, Elliot M. ;

Steiner, Calen A. ;

Johnson, Laura A. ;

Regal, Randolph E. ;

Allen, John I. ;

Cushing, Kelly C. ;

Stidham, Ryan W. ;

Bishu, Shrinivas ;

Kinnucan, Jami A. R. ;

Cohen-Mekelburg, Shirley A. ;

Waljee, Akbar K. ;

Higgins, Peter D. R. .

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2021, 19 (10) :2112-+

[4] Efficacy of Induction Therapy With High-Intensity Tofacitinib in 4 Patients With Acute Severe Ulcerative Colitis [J].

Berinstein, Jeffrey A. ;

Steiner, Calen A. ;

Regal, Randolph E. ;

Allen, John, I ;

Kinnucan, Jami A. R. ;

Stidham, Ryan W. ;

Waljee, Akbar K. ;

Bishu, Shrinivas ;

Aldrich, Leslie B. ;

Higgins, Peter D. R. .

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2019, 17 (05) :988-+

[5] The Management of the Hospitalized Ulcerative Colitis Patient: the Medical–Surgical Conundrum [J].

Carvello M. ;

Watfah J. ;

Włodarczyk M. ;

Spinelli A. .

Current Gastroenterology Reports, 2020, 22 (3)

[6] Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases [J].

Clark, James D. ;

Flanagan, Mark E. ;

Telliez, Jean-Baptiste .

JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (12) :5023-5038

[7] Tofacitinib Salvage Therapy for Children Hospitalized for Corticosteroid- and Biologic-Refractory Ulcerative Colitis [J].

Constant, Brad D. ;

Baldassano, Robert ;

Kirsch, Jacqueline ;

Mitchel, Elana B. ;

Stein, Ronen ;

Albenberg, Lindsey .

JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2022, 75 (06) :724-730

[8] Risk for Herpes Zoster in Tofacitinib-Treated Rheumatoid Arthritis Patients With and Without Concomitant Methotrexate and Glucocorticoids [J].

Curtis, Jeffrey R. ;

Xie, Fenglong ;

Yang, Shuo ;

Bernatsky, Sasha ;

Chen, Lang ;

Yun, Huifeng ;

Winthrop, Kevin .

ARTHRITIS CARE & RESEARCH, 2019, 71 (09) :1249-1254

[9] The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Tofacitinib, a Janus Kinase Inhibitor, in Humans [J].

Dowty, Martin E. ;

Lin, Jinyan ;

Ryder, Tim F. ;

Wang, Weiwei ;

Walker, Gregory S. ;

Vaz, Alfin ;

Chan, Gary L. ;

Krishnaswami, Sriram ;

Prakash, Chandra .

DRUG METABOLISM AND DISPOSITION, 2014, 42 (04) :759-773

[10] Intentional treatment with tofacitinib in a patient with severe refractory ulcerative colitis and concomitant Sars-CoV-2 infection [J].

Festa, Stefano ;

De Biasio, Fabiola ;

Aratari, Annalisa ;

Papi, Claudio .

DIGESTIVE AND LIVER DISEASE, 2022, 54 (11) :1598-1599

← 1 2 3 4 →